243 related articles for article (PubMed ID: 27016228)
1. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
Myers AP; Filiaci VL; Zhang Y; Pearl M; Behbakht K; Makker V; Hanjani P; Zweizig S; Burke JJ; Downey G; Leslie KK; Van Hummelen P; Birrer MJ; Fleming GF
Gynecol Oncol; 2016 Apr; 141(1):43-8. PubMed ID: 27016228
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
Fleming GF; Filiaci VL; Marzullo B; Zaino RJ; Davidson SA; Pearl M; Makker V; Burke JJ; Zweizig SL; Van Le L; Hanjani P; Downey G; Walker JL; Reyes HD; Leslie KK
Gynecol Oncol; 2014 Mar; 132(3):585-92. PubMed ID: 24456823
[TBL] [Abstract][Full Text] [Related]
3. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.
Trédan O; Treilleux I; Wang Q; Gane N; Pissaloux D; Bonnin N; Petit T; Cretin J; Bonichon-Lamichhane N; Priou F; Lavau-Denes S; Mari V; Freyer G; Lebrun D; Alexandre J; Ray-Coquard I
Target Oncol; 2013 Dec; 8(4):243-51. PubMed ID: 23238879
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract][Full Text] [Related]
6. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
[TBL] [Abstract][Full Text] [Related]
8. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
[TBL] [Abstract][Full Text] [Related]
9. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
10. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
11. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract][Full Text] [Related]
12. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
[TBL] [Abstract][Full Text] [Related]
13. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.
Sjödahl G; Lauss M; Gudjonsson S; Liedberg F; Halldén C; Chebil G; Månsson W; Höglund M; Lindgren D
PLoS One; 2011 Apr; 6(4):e18583. PubMed ID: 21533174
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
[TBL] [Abstract][Full Text] [Related]
16. Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.
Lim JS; Gopalappa R; Kim SH; Ramakrishna S; Lee M; Kim WI; Kim J; Park SM; Lee J; Oh JH; Kim HD; Park CH; Lee JS; Kim S; Kim DS; Han JM; Kang HC; Kim HH; Lee JH
Am J Hum Genet; 2017 Mar; 100(3):454-472. PubMed ID: 28215400
[TBL] [Abstract][Full Text] [Related]
17. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
[TBL] [Abstract][Full Text] [Related]
18. Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.
Nathan N; Keppler-Noreuil KM; Biesecker LG; Moss J; Darling TN
Dermatol Clin; 2017 Jan; 35(1):51-60. PubMed ID: 27890237
[TBL] [Abstract][Full Text] [Related]
19. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
Cohen Y; Shalmon B; Korach J; Barshack I; Fridman E; Rechavi G
Gynecol Oncol; 2010 Jan; 116(1):88-91. PubMed ID: 19853286
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]